SurModics, Inc. (NASDAQ:SRDX)

CAPS Rating: 4 out of 5

Develops, manufactures and markets innovative surface modification and drug delivery technologies for the healthcare industry.

Results 1 - 16 of 16

Recs

0
Member Avatar squidfungus (< 20) Submitted: 10/5/2012 5:04:28 PM : Outperform Start Price: $20.90 SRDX Score: -44.24

This is a pharmaceutical company that company that has very limited competition. The manufacture a product that requires FDA approval to enter as a competitor.

Recs

0
Member Avatar phatchips767 (< 20) Submitted: 1/23/2012 6:18:17 PM : Outperform Start Price: $14.47 SRDX Score: -18.39

trackfeltland likeeed em.. Did well in two months.

Recs

0
Member Avatar EclecticRecluse (79.76) Submitted: 5/16/2011 7:36:54 AM : Outperform Start Price: $15.12 SRDX Score: -20.91

Earnings Estimates Revised Upward

Recs

0
Member Avatar jsgant13 (98.89) Submitted: 11/30/2010 10:36:24 AM : Outperform Start Price: $9.23 SRDX Score: +40.16

oozing alpha activist play

Recs

0
Member Avatar paggles (47.71) Submitted: 2/14/2009 2:25:27 AM : Outperform Start Price: $18.99 SRDX Score: -147.54

Well positioned for growth in healthcare sector. Could be bought by major drug company by the end of 2009. Several things to like for the beaten down price

Recs

1
Member Avatar rklapman (84.47) Submitted: 12/15/2008 8:41:00 PM : Outperform Start Price: $23.32 SRDX Score: -145.01

Expect takeover by JNJ

Recs

0
Member Avatar harrytong (93.30) Submitted: 10/17/2008 3:36:22 AM : Underperform Start Price: $25.60 SRDX Score: +143.17

expensive.

Recs

0
Member Avatar HoldSideAnalyst (< 20) Submitted: 7/30/2007 5:23:31 PM : Outperform Start Price: $47.60 SRDX Score: -98.35

Stent worries overdone. Regardless, this company has real opportunities beyond the stent market.

Recs

0
Member Avatar aaroger (83.80) Submitted: 7/20/2007 5:20:51 AM : Underperform Start Price: $46.98 SRDX Score: +91.98

53

Recs

0
Member Avatar cccruz (35.42) Submitted: 7/6/2007 9:38:51 PM : Outperform Start Price: $52.37 SRDX Score: -97.60

Still has 5 potential opthamology deals to be signed in addition to Merck. Diverse portfolio of customes and products. Great patent coverage. No debt. Recent stock buyback. High short interest due to investors who feel Surmodics is a one trick pony with stents.

Recs

0
Member Avatar skc0001 (< 20) Submitted: 6/18/2007 3:10:08 AM : Outperform Start Price: $37.90 SRDX Score: -83.68

Proposed by Good People

Recs

0
Member Avatar marionvb (61.50) Submitted: 2/2/2007 9:05:58 PM : Outperform Start Price: $36.94 SRDX Score: -91.56

new antibiotic beads, JNJ business recovering, no debt

Recs

0
Member Avatar mrnew (48.99) Submitted: 1/19/2007 2:50:10 PM : Outperform Start Price: $31.13 SRDX Score: -83.85

Value of the pipeline is being overwhelmed by the debate on the value of coated stents.

Recs

0
Member Avatar morgnlll (< 20) Submitted: 12/9/2006 9:19:04 PM : Outperform Start Price: $33.13 SRDX Score: -88.99

Will win out in the coated stent race.

Recs

0
Member Avatar jddixon1 (< 20) Submitted: 10/10/2006 1:46:09 PM : Outperform Start Price: $34.19 SRDX Score: -97.80

Market for their coatings will increase as boomers age and we all get .... larger.

Recs

0
Member Avatar hermitinvestor (60.99) Submitted: 9/13/2006 4:33:44 PM : Outperform Start Price: $35.29 SRDX Score: -103.78

Versatile, well protected technology makes anyone's medical device better. Major new business coming.

Results 1 - 16 of 16

Featured Broker Partners


Advertisement